Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock
DOI:
https://doi.org/10.1532/hsf.3263Keywords:
extracorporeal membrane oxygenation(ECMO), refractory, cardiogenic, shockAbstract
Background: Many clinicians do not know under what exact conditions extracorporeal membrane oxygenation (ECMO) can get the best results. In this study, we explored the optimal indications for ECMO in patients with refractory cardiogenic shock.
Methods: From October 2014 to November 2019, 23 patients with refractory cardiogenic shock were treated with ECMO in our hospital, including 11 cases with acute left anterior myocardial infarction, 3 with acute left inferior and right ventricular myocardial infarction, and 9 with fulminant myocarditis. These cases were divided into survivors (n = 10) and nonsurvivors (n = 13), and the clinical data of the 2 groups were compared.
Results: The weaning rate of ECMO was 60.9%. The discharge survival rate was 43.5%. There were significant differences in age, sequential organ failure assessment (SOFA) score, vasoactive-inotropic (VIS) score, lactic acid concentrations, primary disease, and smoking history between survivors and nonsurvivors before ECMO (P < .05). There were significant differences in blood pressure (systolic and diastolic), oxygen partial pressure, and left ventricular ejection fraction between survivors and nonsurvivors 1 day before the removal of ECMO (P < .05).
Conclusions: The reversibility of the primary disease causing refractory cardiogenic shock is critical to the survival rate of ECMO. Etiological treatment is essential, and extra attention should be paid to the use of ECMO in patients with irreversible primary disease. ECMO should be regarded as a first aid device and is not suitable for long-term cardiac assistance; left ventricular assist or heart transplantation is a better option.
References
Chen ZW, Yu ZQ, Yang HB, et al. Rapid predictors for the occurrence of reduced left ventricular ejection fraction between LAD and non-LAD related ST-elevation myocardial infarction. BMC Cardiovasc Disord 2016;16:3.
Chong SZ, Fang CY, Fang HY, et al. Associations with the in-hospital survival following extracorporeal membrane oxygenation in adult acute fulminant myocarditis. J Clin Med 2018;7:E452.
Goldberg RJ, Makam RC, Yarzebski J, McManus DD, Lessard D, Gore JM. Decade-long trends (2001-2011) in the incidence and hospital death rates associated with the in-hospital development of cardiogenic shock after acute myocardial infarction. Circ Cardiovasc Qual Outcomes 2016;9:117-125.
Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST elevation myocardial infarction in the United States. J Am Heart Assoc 2014;3:e000590.
Lee SN, Hwang YM, Kim GH, et al. Primary percutaneous coronary intervention ameliorates complete atrioventricular block complicating acute inferior myocardial infarction. Clin Interv Aging 2014;9:2027-2031.
Liao X, Li B, Cheng Z. Extracorporeal membrane oxygenation in adult patients with acute fulminant myocarditis: Clinical outcomes and risk factor analysis. Herz 2018;43:728-732.
Lin KM, Li MH, Hsieh KS, et al. Impact of extracorporeal membrane oxygenation on acute fulminant myocarditis-related hemodynamic compromise arrhythmiain children. Pediatr Neonatol 2016;57:480-487.
Matsumoto M, Asaumi Y, Nakamura Y, et al. Clinical determinants of successful weaning from extracorporeal membrane oxygenation in patients with fulminant myocarditis. ESC Heart Fail 2018;5:675-684.
Montero S, Aissaoui N, Tadié JM, et al. Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort. Int J Cardiol 2018;253:105-112.
Nasr VG, Raman L, Barbaro RP, et al. Highlights from the Extracorporeal Life Support Organization Registry: 2006-2017. ASAIO J 2019;65:537-544.
Rejmstad P, Johansson JD, Haj-Hosseini N, Wardell K. A method for monitoring of oxygen saturation changes in brain tissue using diffuse reflectance spectroscopy. J Biophotonics 2017;10:446-455.
Reynolds HR, Hochman JS. Cardiogenic shock: Current concepts and improving outcomes. Circulation 2008;117:686-697.
Sandhu A, McCoy LA, Negi SI, et al. Use of mechanical circulatory support in patients undergoing percutaneous coronary intervention: Insights from the National Cardiovascular Data Registry. Circulation 2015;132:1243-1251.
Smarz K, Zaborska B, Jaxa-Chamiec T, Tysarowski M, Budaj A. Right ventricular systolic function as a marker of prognosis after ST-elevation inferior myocardial infarction 5-year follow-up. Int J Cardiol 2016;221:549-553.
Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J 2015;36:1223-1230.
Thiele H, Zeymer U, Neumann FJ, et al. IABP SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287-1296.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
